Diagnosis and management of Hodgkin lymphoma in children, adolescents, and young adults

Classic Hodgkin lymphoma (HL) is the most common cancer in adolescent young adult (AYA) patients between ages 15 and 19, and accounts for 18% of cancer diagnoses annually in children and AYAs in the United States [1]. Outcomes in HL are extremely favorable with overall survival rates exceeding 90%. These excellent outcomes, however come at the cost of increased risk for long term toxicity due to chemotherapy and/or radiation. This risk may be improved as novel therapies are introduced that may successfully cure patients with the potential to reduce acute and long-term toxicity. Here, we will review the current state of the field in pediatric HL including the use chemotherapy and immunotherapy agents in upfront and relapsed disease, risk stratification, the evolving role for radiation, and recent research into the biology of HL in children and AYAs.

留言 (0)

沒有登入
gif